Jun 2026 (Q2 FY26) — Jul 30, 2026
Wave Life Sciences Q2 FY26 — Obesity and AATD Programs Advance, Regulatory Pathway for 006 Explored
Read the full callWave Life Sciences (WVE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Wave Life Sciences earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 2.3 | −73.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -3248.3 | −2641.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -69.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.19 +3.24% · +$0.1
Performance −59.6% 1Y
1Y: $7.89 on 14 Oct 2025 → $3.19. High $21.31 (9 Dec 2025), low $3.09 (14 Oct 2026).
- Previous close
- $3.09
- 52-week range
- $3.09 – $21.31
- One year
- −60.57%
Overview
- Symbol
- WVE
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Wave Life Sciences earnings calls (WVE)
Financials
What the filings say
Net profit, year on year: −37% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | 9 | 9 | — | — | 38 | 2 |
| Operating profit | -64 | 23 | -50 | -53 | -56 | -56 | -31 | -74 |
| Operating margin | — | — | −542.8% | −606.5% | — | — | −81.8% | −3248.3% |
| Other income | 2 | 6 | 3 | 2 | 3 | 3 | 5 | 4 |
| Profit before tax | -62 | 29 | -47 | -50 | -54 | -53 | -26 | -69 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -62 | 29 | -47 | -50 | -54 | -53 | -26 | -69 |
| EPS ($ per share) | -0.47 | — | -0.29 | -0.31 | -0.32 | — | -0.13 | -0.34 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 375 | 540 | 694 | 750 | 803 | 935 | 1,175 | 1,616 |
| Reserves | -340 | -533 | -683 | -806 | -967 | -1,025 | -1,122 | -1,326 |
| Total liabilities | 215 | 213 | 189 | 167 | 184 | 227 | 135 | 112 |
| Fixed assets | 40 | 36 | 29 | 22 | 17 | 13 | 10 | 7 |
| Total assets | 296 | 284 | 279 | 207 | 146 | 275 | 352 | 638 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23 | -188 | -116 | -89 | -128 | -19 | -151 | -187 |
| Cash from investing | -10 | -4 | -1 | -1 | -1 | -1 | -1 | -1 |
| Cash from financing | 65 | 164 | 155 | 56 | 67 | 133 | 254 | 488 |
| Net cash flow | 32 | -28 | 37 | -34 | -62 | 112 | 102 | 300 |
| Capital expenditure | -10 | -4 | -1 | -1 | -1 | -1 | -1 | -1 |
| Free cash flow | -33 | -192 | -117 | -90 | -129 | -21 | -152 | -188 |
Insider filings
94 filings between Nov 13, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
$82.56M
6 purchases by 2 insiders
Sales
$16.18M
47 sales by 11 insiders
91% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 28
- Option exercise — converted options into shares
Also filed: 1 conversion.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $54.63M | — | Mar 30, 2026 |
| GSK plc | $27.93M | — | Dec 11, 2025 |
| Francis Chris | — | $7.10M | Feb 26, 2026 |
| Moran Kyle | — | $4.15M | Feb 9, 2026 |
| Tan Aik Na | — | $1.83M | Aug 11, 2026 |
| HENRY CHRISTIAN O | — | $1.37M | Dec 8, 2025 |
| Rawcliffe Adrian | — | $806.6K | Aug 12, 2026 |
| Verdine Gregory L. | — | $269.5K | Dec 8, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | HENRY CHRISTIAN O Director | Award | 10,700 | $0 |
| Oct 5, 2026 | Tan Aik Na Director | Award | 10,700 | $0 |
| Oct 5, 2026 | Rawcliffe Adrian Director | Award | 10,700 | $0 |
| Oct 5, 2026 | CORRIGAN MARK Director | Award | 10,700 | $0 |
| Oct 5, 2026 | Verdine Gregory L. Director | Award | 10,700 | $0 |
| Oct 5, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Award | 10,700 | $0 |
| Oct 5, 2026 | TAKANASHI KEN Director | Award | 10,700 | $0 |
| Oct 5, 2026 | Wagner Heidi L Director | Award | 10,700 | $0 |
| Aug 12, 2026 | Rawcliffe Adrian Director | Sale 10b5-1 plan | 12,700 | $67.2K |
| Aug 11, 2026 | Tan Aik Na Director | Sale 10b5-1 plan | 432 | $2.6K |
| Aug 11, 2026 | Wagner Heidi L Director | Sale 10b5-1 plan | 7,000 | $42.1K |
| Aug 11, 2026 | TAKANASHI KEN Director | Sale 10b5-1 plan | 3,864 | $23.2K |
| Aug 11, 2026 | Wagner Heidi L Director | Option exercise 10b5-1 plan | 7,000 | $41.8K |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 971,091 | $6.31M |
| Mar 27, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 2,495,623 | $16.05M |
| Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 351,224 | $2.24M |
| Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 4,954,558 | $30.02M |
| Mar 23, 2026 | TAKANASHI KEN Director | Conversion | 3,901,348 | $0 |
| Feb 26, 2026 | Francis Chris See Remarks | Sale 10b5-1 plan | 15,294 | $229.4K |
| Feb 26, 2026 | Francis Chris See Remarks | Sale 10b5-1 plan | 17,900 | $270.2K |
| Feb 26, 2026 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 15,294 | $72.6K |
| Feb 26, 2026 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 17,900 | $69.3K |
| Feb 9, 2026 | BOLNO PAUL President and CEO | Sale | 10,480 | $141.0K |
| Feb 9, 2026 | Moran Kyle Chief Financial Officer | Sale | 3,588 | $48.3K |
| Feb 9, 2026 | Francis Chris See Remarks | Sale | 1,883 | $25.3K |
| Feb 9, 2026 | Vargeese Chandra See Remarks | Sale | 3,228 | $43.4K |
| Feb 5, 2026 | Moran Kyle Chief Financial Officer | Award | 45,625 | $0 |
| Feb 5, 2026 | Francis Chris See Remarks | Award | 38,750 | $0 |
| Feb 5, 2026 | Vargeese Chandra See Remarks | Award | 45,625 | $0 |
| Feb 5, 2026 | BOLNO PAUL President and CEO | Award | 165,000 | $0 |
| Jan 2, 2026 | Francis Chris See Remarks | Sale 10b5-1 plan | 1,295 | $21.6K |
| Jan 2, 2026 | Francis Chris See Remarks | Sale 10b5-1 plan | 8,080 | $128.6K |
| Jan 2, 2026 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 9,375 | $29.4K |
| Dec 11, 2025 | GSK plc 10% owner | Purchase | 1,470,000 | $27.93M |
| Dec 9, 2025 | Moran Kyle Chief Financial Officer | Sale 10b5-1 plan | 50,000 | $1.00M |
| Dec 9, 2025 | Moran Kyle Chief Financial Officer | Option exercise 10b5-1 plan | 50,000 | $524.0K |
| Dec 9, 2025 | Moran Kyle Chief Financial Officer | Sale 10b5-1 plan | 36 | $729 |
| Dec 9, 2025 | Moran Kyle Chief Financial Officer | Option exercise 10b5-1 plan | 36,000 | $294.1K |
| Dec 8, 2025 | CORRIGAN MARK Director | Sale 10b5-1 plan | 6,515 | $91.6K |
| Dec 8, 2025 | CORRIGAN MARK Director | Sale 10b5-1 plan | 9,600 | $125.7K |
| Dec 8, 2025 | Tan Aik Na Director | Sale 10b5-1 plan | 7,494 | $112.4K |
| Dec 8, 2025 | Francis Chris See Remarks | Sale 10b5-1 plan | 37,500 | $528.0K |
| Dec 8, 2025 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 37,500 | $117.8K |
| Dec 8, 2025 | Francis Chris See Remarks | Sale 10b5-1 plan | 9,375 | $140.6K |
| Dec 8, 2025 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 107,400 | $415.6K |
| Dec 8, 2025 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 9,375 | $29.4K |
| Dec 8, 2025 | Francis Chris See Remarks | Sale 10b5-1 plan | 45,882 | $665.3K |
| Dec 8, 2025 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 45,882 | $217.9K |
| Dec 8, 2025 | Francis Chris See Remarks | Sale 10b5-1 plan | 107,400 | $1.56M |
| Dec 8, 2025 | Francis Chris See Remarks | Option exercise 10b5-1 plan | 28,125 | $88.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Wave Life Sciences Ltd.
Free account. Everything above stays public.
Write why you follow Wave Life Sciences Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading